<DOC>
	<DOCNO>NCT01444716</DOCNO>
	<brief_summary>The goal clinical research study learn ofatumumab help control CLL . The safety drug also study . Ofatumumab design bind surface leukemia cell . This may cause leukemia cell die .</brief_summary>
	<brief_title>Phase II Study Ofatumumab Elderly Patients With Chronic Lymphocytic Leukemia ( CLL )</brief_title>
	<detailed_description>Study Drug Administration : If find eligible take part study , receive ofatumumab vein every week 4 week . After , receive every month . Each infusion last 4 hour . Before receive ofatumumab , give drug help reduce risk side effect . - You take Tylenol ( acetaminophen ) mouth . - You receive diphenhydramine vein 5 minute . - You receive steroid vein 5 minute . - You take allopurinol mouth first 14 day treatment . Study Visits : Every week , blood ( 1 teaspoon ) drawn routine test . Every month , physical exam . If doctor think need , also bone marrow biopsy check status disease . After Month 6 every 6 month , bone marrow biopsy aspiration check status disease . Length Treatment : You may continue receive study drug 12 month . You longer able take study drug disease get bad , intolerable side effect occur , unable follow study direction . This investigational study . Ofatumumab FDA approve treatment chronic lymphocytic leukemia relapse . Its use study initial treatment CLL investigational . Up 34 patient take part study . All enrol MD Anderson .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>1 . Patients chronic lymphocytic leukemia require treatment age &gt; 65 time signing informed consent . 2 . The Eastern Cooperative Oncology Group ( ECOG ) /World Health Organization ( WHO ) performance status 23.or patient chronic lymphocytic leukemia require treatment age &gt; 65 year time signing informed consent ECOG/WHO performance status 01 CIRS Charlson comorbidity score 2 high . 3 . Adequate renal hepatic function ( creatinine &lt; 2mg/dL eGFR 30cc/minute , bilirubin &lt; 2mg/dL ) . Patients renal liver dysfunction due organ infiltration lymphocyte may eligible discussion study chairman . Patients Gilbert 's syndrome eligible . 1 . Patients document prolymphocytic leukemia ( prolymphocytes 55 % blood ) . 2 . Known positivity HIV . 3 . Hepatitis B ( HB ) define positive test HBsAg . In addition , negative HGsAg HBcAb positive ( regardless HBsAb status ) , HB DNA test perform positive subject exclude . 4 . Prior treatment chronic lymphocytic leukemia . 5 . Concurrent chemotherapy , radiotherapy , immunotherapy , include monoclonal antibody . Localized radiotherapy area compromise bone marrow function apply . Patients malignancy indolent behavior prostate cancer treat radiation surgery enrol study long reasonable expectation cure treatment modality receive . 6 . Any serious medical condition , laboratory abnormality , psychiatric illness place subject unacceptable risk he/she participate study . 7 . Any known hypersensitivity ofatumumab component .</criteria>
	<gender>All</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Advanced Cancers</keyword>
	<keyword>Leukemia</keyword>
	<keyword>Chronic Lymphocytic Leukemia</keyword>
	<keyword>CLL</keyword>
	<keyword>Elderly</keyword>
	<keyword>Ofatumumab</keyword>
	<keyword>Arzerra</keyword>
</DOC>